Company intelligence / Profile preview
Hangzhou Gongchu Biotechnology Co., Ltd.
Hangzhou, Zhejiang Sheng/Zhejiang Province, China
- Ownership
- Private
- Development stage
- Other
01
Overview
The company’s lead asset, an oncolytic vaccinia virus targeting STRIP1, has entered Phase I clinical trials in China for multiple solid tumor indications including high grade glioma and advanced malignant neoplasms. No published results yet.
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic viruses
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Hangzhou Gongchu Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hangzhou Gongchu Biotechnology Co., Ltd..